AstraZeneca's MedImmune unit has presented positive Phase IIb data at the American College of Rheumatology (ACR) meeting this week from two products highlighted by CEO Pascal Soriot as 'ones to watch' as he fended off Pfizer's unwanted advances earlier this year (scripintelligence.com, 28 May 2014). However, their progress into Phase III is not assured as AstraZeneca is waiting on data from other trials before making a decision on how to proceed.
Sifalimumab (MEDI-545), a monoclonal antibody targeting interferon for treatment of systemic lupus erythematosus (SLE or lupus), and mavrilimumab, a monoclonal...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
